By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tonix Pharmaceuticals, Inc. 

509 Madison Ave.
Suite 306
New York  New York  10022  U.S.A.
Phone: 212-980-9155 Fax: 212-923-5700




Company News
Tonix Pharma (TNXP) Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference 1/11/2017 7:00:34 AM
Tonix Pharma (TNXP)’s PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA 12/19/2016 7:57:23 AM
Tonix Pharma (TNXP) Presented New Clinical Results From Sub-Group Analysis Of Phase II Atease Study In Military-Related Posttraumatic Stress Disorder (PTSD) 12/8/2016 7:50:14 AM
Tonix Pharma (TNXP) Reports Third Quarter 2016 Financial Results 11/11/2016 7:59:22 AM
Tonix Pharma (TNXP) To Present New Clinical Results From Retrospective Analysis Of Phase II AtEase Study In Military-Related PTSD 11/10/2016 8:50:21 AM
Tonix Pharma (TNXP) Completes $5.2 Million Underwritten Public Offering 11/1/2016 11:07:00 AM
Tonix Pharma (TNXP) Prices $5.2 Million Underwritten Public Offering 10/26/2016 8:13:09 AM
Tonix Pharma (TNXP) Announces Proposed Underwritten Public Offering Of Common Stock And Warrants 10/26/2016 7:55:21 AM
Tonix Pharma (TNXP) To Host Posttraumatic Stress Disorder (PTSD) Awareness Day 10/19/2016 7:52:12 AM
Tonix Pharma (TNXP) To Present At Dawson James Securities 2016 Small Cap Growth Stock Conference 10/13/2016 7:57:26 AM